Identification of conserved subdominant HIV type 1 CD8+ T cell epitopes restricted within common HLA supertypes for therapeutic HIV type 1 vaccines

AIDS Research and Human Retroviruses

Volumn 28, Issue 11, 2012, Pages 1434-1443

  Karlsson, Ingrid ^a   Kløverpris, Henrik ^a,b   Jensen, Kristoffer Jarlov ^a,c   Stryhn, Anette ^d   Buus, Søren ^d   Karlsson, Annika ^e   Vinner, Lasse ^a   Goulder, Philip ^b   Fomsgaard, Anders ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c BANDIM HEALTH PROJECT   (Guinea-Bissau)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ENV67 PROTEIN; EPITOPE; GAG148 PROTEIN; GAG150 PROTEIN; GAG433 PROTIN; GAMMA INTERFERON; HLA A1 ANTIGEN; HLA A2 ANTIGEN; HLA A3 ANTIGEN; HLA B44 ANTIGEN; HLA B7 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEF107 PROTEIN; NEF73 PROTEIN; POL311 PROTEIN; POL313 PROTEIN; POL593 PROTEIN; POL606 PROTEIN; POL934 PROTEIN; POL973 PROTEIN; TETRAMER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIF101 PROTEIN; VIF23 PROTEIN; VPU66 PROTEIN;

ADULT; ALLELE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENMARK; DRUG SAFETY; FEMALE; GENOTYPE; GEOGRAPHIC DISTRIBUTION; GUINEA-BISSAU; HLA TYPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; VIRUS GENOME;

ADOLESCENT; ADULT; AIDS VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DENMARK; DRUG EVALUATION, PRECLINICAL; EPITOPES, T-LYMPHOCYTE; FEMALE; GUINEA-BISSAU; HISTOCOMPATIBILITY TESTING; HIV INFECTIONS; HIV-1; HLA ANTIGENS; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PREDICTIVE VALUE OF TESTS; SEQUENCE ALIGNMENT; VACCINES, DNA;

EID: 84868515590     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0081     Document Type: Article

References (40)

1. UNAIDS. UNAIDS Report on the Global AIDS Epidemic 2010. http://www.unaids.org/globalreport/Global-report.htm.
2. da Silva ZJ, Oliveira I, Andersen A, et al.: Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: Is HIV-2 disappearing? AIDS 2008;22(10):1195-1202.
3. Autran B, Carcelain G, Combadiere B, and Debre P: Therapeutic vaccines for chronic infections. Science 2004;305(5681):205-208.
4. Hanke T and McMichael AJ: Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat Med 2000;6(9):951-955.
5. Watkins DI: The hope for an HIV vaccine based on induction of CD8+ T lymphocytes-a review. Mem Inst Oswaldo Cruz 2008;103(2):119-129.
6. Goulder PJ and Watkins DI: HIV and SIV CTL escape: Implications for vaccine design. Nat Rev Immunol 2004;4(8):630-640.
7. Chen W, Anton LC, Bennink JR, and Yewdell JW: Dissecting the multifactorial causes of immunodominance in class I-re-stricted T cell responses to viruses. Immunity 2000;12(1):83-93.
8. Rodriguez F, Harkins S, Slifka MK, and Whitton JL: Im-munodominance in virus-induced CD8(+) T-cell responses is dramatically modified by DNA immunization and is regulated by gamma interferon. J Virol 2002;76(9):4251-4259.
9. Yewdell JW: Confronting complexity: Real-world immuno-dominance in antiviral CD8+ T cell responses. Immunity 2006;25(4):533-543.
10. Frahm N, Kiepiela P, Adams S, et al.: Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 2006; 7(2):173-178.
11. Vinner L, Holmgren B, Jensen KJ, et al.: Sequence analysis of HIV-1 isolates from Guinea-Bissau: Selection of vaccine epitopes relevant in both West African and European countries. APMIS 2011;119(8):487-497.
12. Thorn M, Tang S, Therrien D, et al.: Sequence conservation of subdominant HLA-A2-binding CTL epitopes in HIV-1 clinical isolates and CD8+ T-lymphocyte cross-recognition may explain the immune reaction in infected individuals. APMIS 2007;115(6):757-768.
13. Andresen BS, Vinner L, Tang S, et al.: Characterization of near full-length genomes of HIV type 1 strains in Denmark: Basis for a universal therapeutic vaccine. AIDS Res Hum Retroviruses 2007;23(11):1442-1448.
14. Corbet S, Nielsen HV, Vinner L, et al.: Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus type 1-specific CTL epi-topes. J Gen Virol 2003;84(Pt 9):2409-2421.
15. Kloverpris H, Karlsson I, Bonde J, et al.: Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes. AIDS 2009;23(11):1329-1340.
16. Hemelaar J, Gouws E, Ghys PD, and Osmanov S: Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011;25(5):679-689.
17. Montavon C, Toure-Kane C, Liegeois F, et al.: Most env and gag subtype A HIV-1 viruses circulating in West and West Central Africa are similar to the prototype AG recombinant virus IBNG. J Acquir Immune Defic Syndr 2000;23(5):363-374.
18. Esbjornsson J, Mild M, Mansson F, Norrgren H, and Med-strand P: HIV-1 molecular epidemiology in Guinea-Bissau, West Africa: Origin, demography and migrations. PLoS One 2011;6(2):e17025.
19. Sette A and Sidney J: Nine major HLA class I supertypes account for the vast preponderance of HLA-A and-B polymorphism. Immunogenetics 1999;50(3-4):201-212.
20. Sidney J, Peters B, Frahm N, Brander C, and Sette A: HLA class I supertypes: A revised and updated classification. BMC Immunol 2008;9:1.
21. Perez CL, Larsen MV, Gustafsson R, et al.: Broadly immu-nogenic HLA Class I supertype-restricted elite CTL epitopes recognized in a diverse population infected with different HIV-1 subtypes. J Immunol 2008;180(7):5092-5100.
22. Nielsen M, Lundegaard C, Blicher T, et al.: NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and-B locus protein of known sequence. PLoS One 2007;2(8):e796.
23. Leisner C, Loeth N, Lamberth K, et al.: One-pot, mix-and-read peptide-MHC tetramers. PLoS One 2008;3(2):e1678.
24. Harndahl M, Rasmussen M, Roder G, and Buus S: Real-time, high-throughput measurements of peptide-MHC-I dissociation using a scintillation proximity assay. J Immunol Methods 2011;374(1-2):5-12.
25. Spinola H, Bruges-Armas J, Middleton D, and Brehm A: HLA polymorphisms in Cabo Verde and Guinea-Bissau inferred from sequence-based typing. Hum Immunol 2005; 66(10):1082-1092.
26. Spinola C, Bruges-Armas J, Brehm A, and Spinola H: HLA-A polymorphisms in four ethnic groups from Guinea-Bissau (West Africa) inferred from sequence-based typing. Tissue Antigens 2008;72(6):593-598.
27. Yindom LM, Leligdowicz A, Martin MP, et al.: Influence of HLA class I and HLA-KIR compound genotypes on HIV-2 infection and markers of disease progression in a Manjako community in West Africa. J Virol 2010;84(16):8202- 8208.
28. Erup Larsen M, Kloverpris H, Stryhn A, et al.: HLAr-estrictor-a tool for patient-specific predictions of HLA restriction elements and optimal epitopes within peptides. Immunogenetics 2011;63(1):43-55.
29. Ueno T, Motozono C, Dohki S, et al.: CTL-mediated selective pressure influences dynamic evolution and pathogenic functions of HIV-1 Nef. J Immunol 2008;180(2):1107-1116.
30. The Los Alamos HIV immunology databases. http://www.hiv.lanl.gov/content/ immunology.
31. Fischer W, Perkins S, Theiler J, et al.: Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 2007;13(1):100-106.
32. Letourneau S, Im EJ, Mashishi T, et al.: Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One 2007;2(10):e984.
33. Ranasinghe SR, Kramer HB, Wright C, et al.: The antiviral efficacy of HIV-specific CD8 T-cells to a conserved epitope is heavily dependent on the infecting HIV-1 isolate. PLoS Pa-thog 2011;7(5):e1001341.
34. Matthews PC, Prendergast A, Leslie A, et al.: Central role of reverting mutations in HLA associations with human immunodeficiency virus set point. J Virol 2008;82(17):8548-8559.
35. Grossman Z, Meier-Schellersheim M, Paul WE, and Picker LJ: Pathogenesis of HIV infection: What the virus spares is as important as what it destroys. Nat Med 2006;12(3):289-295.
36. van Grevenynghe J, Cubas RA, Noto A, et al.: Loss of memory B cells during chronic HIV infection is driven by Foxo3a-and TRAIL-mediated apoptosis. J Clin Invest 2011; 121(10):3877-3888.
37. Harari A, Petitpierre S, Vallelian F, and Pantaleo G: Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: Changes after antiretroviral therapy. Blood 2004;103(3):966-972.
38. Lichterfeld M, Kaufmann DE, Yu XG, et al.: Loss of HIV-1-specific CD8 + T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4 + T cells. J Exp Med 2004;200(6):701-712.
39. Rao X, Hoof I, Costa AI, van Baarle D, and Kesmir C: HLA class I allele promiscuity revisited. Immunogenetics 2011; 63(11):691-701.
40. Fomsgaard A, Karlsson I, Gram G, et al.: Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01. Vaccine 2011; 29(40):7067-7074.